Replimune Group Inc
NASDAQ:REPL
Replimune Group Inc
NASDAQ:REPL
Price:
5.27 USD
3.33%
Market Closed
Updated:
Jun 1, 2024
Replimune Group Inc
Accrued Liabilities
|
Replimune Group Inc
Accrued Liabilities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Accrued Liabilities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Replimune Group Inc
NASDAQ:REPL
|
Accrued Liabilities
$31.8m
|
CAGR 3-Years
51%
|
CAGR 5-Years
66%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accrued Liabilities
$5.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accrued Liabilities
$14.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
12%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accrued Liabilities
$2.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
39%
|
CAGR 10-Years
28%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accrued Liabilities
$2.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
28%
|
See Also
What is Replimune Group Inc's Accrued Liabilities?
Accrued Liabilities
31.8m
USD
31.8m
USD
Based on the financial report for Mar 31, 2024, Replimune Group Inc's Accrued Liabilities amounts to 31.8m USD.
What is Replimune Group Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
66%
66%
Over the last year, the Accrued Liabilities growth was 40%. The average annual Accrued Liabilities growth rates for Replimune Group Inc have been 51% over the past three years , 66% over the past five years .
You don't have any saved screeners yet
